BulgariaTuberculosis profile
Population  2017 7.1 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.091 (0.089–0.093) 1.3 (1.3–1.3)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0 (0–0.01)
Incidence  (includes HIV+TB) 1.7 (1.3–2.1) 24 (18–30)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.04 (0.03–0.06)
Incidence (MDR/RR-TB)** 0.037 (0.015–0.069) 0.53 (0.22–0.98)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.081 (0.077–0.086) 0.48 (0.42–0.54) 0.56 (0.48–0.64)
Males 0.09 (0.084–0.095) 1 (0.84–1.2) 1.1 (0.9–1.4)
Total 0.17 (0.16–0.18) 1.5 (1.2–1.9) 1.7 (1.3–2.1)
TB case notifications, 2017  
Total cases notified  
Total new and relapse  
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status  
          - % pulmonary  
          - % bacteriologically confirmed among pulmonary  
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017  
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.06 (0.04–0.07)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 3 <1%
          - on antiretroviral therapy 3 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
 
(–)
Estimated % of TB cases with MDR/RR-TB 1.2% (0.49–2.5) 19% (11–29)  
% notified tested for rifampicin resistance     29
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 29, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 27, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2016    
Previously treated cases registered in 2016    
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015    
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions) 8.8
Funding source: 84% domestic, 16% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-25 Data: www.who.int/tb/data